Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00467506 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma

Study acronym: RIT in MTC
StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Amendment history

  1. Minor

    Study Identification, Study Status, References

    v4

  2. Minor

    Trial status: Active, Not Recruiting to Completed

    Study sites: 13 to 11; Primary completion date: Jan 2011

    Study Status, Contacts/Locationsv3

  3. Minor

    Trial status: Recruiting to Active, Not Recruiting

    Completion date: Jan 2011; Site details revised at 13 of 13 sites

    Study Identification, Study Status, Contacts/Locationsv2

  4. Minor

    Study First Submitted

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase II clinical trial assessing efficacy and toxicity of pretargeted radioimmunotherapy using anti-CEAxanti-DTPA bispecific antibody and di-DTPA-131I peptide in patients with reccurrence of medullary thyroid carcinoma (abnormal calcitonin level and biomarkers doubling time lower than 5 years)
Trial Details
NCT Number NCT00467506
Lead Sponsor Nantes University Hospital
Conditions Thyroid Neoplasms
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov